Skip to main content

Main menu

  • Home
  • Current issue
  • Early View
  • Archive
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Institutional open access agreements
    • Peer reviewer login
    • WoS Reviewer Recognition Service
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • Early View
  • Archive
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Institutional open access agreements
    • Peer reviewer login
    • WoS Reviewer Recognition Service
  • Alerts
  • Subscriptions

Objective cough frequency monitoring in real-world practice

Ji-Hyang Lee, Woo-Jung Song, Eva Millqvist, Alyn H. Morice
ERJ Open Research 2021 7: 00545-2021; DOI: 10.1183/23120541.00545-2021
Ji-Hyang Lee
1Dept of Allergy and Clinical Immunology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Woo-Jung Song
1Dept of Allergy and Clinical Immunology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Woo-Jung Song
  • For correspondence: swj0126@gmail.com
Eva Millqvist
2Dept of Internal Medicine/Respiratory Medicine and Allergology, Sahlgrenska University Hospital, University of Gothenburg, Gothenburg, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alyn H. Morice
3Respiratory Medicine, Institute for Clinical and Applied Health Research, Hull York Medical School, Hull, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Alyn H. Morice
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

There are possibilities and obstacles to the use of objective cough monitoring in real-world practice. Advances in technology will overcome the difficulties and continuous real-time cough monitoring will then provide a valuable tool in cough management. https://bit.ly/3lu5cfk

For those of us seeing patients with chronic cough, there is one great advantage in comparison with other specialities dealing with recurrent symptoms such as migraine, chronic pain, and psychiatric conditions. We can measure cough.

There are three metrics available to us. Inhalational cough challenge with a variety of tussive agents has been used since the 1950s. This has given us clear evidence that cough reflex hypersensitivity is a cardinal feature of the condition. However, like the bronchial hyperreactivity seen in asthma, this is “not necessary or sufficient to make the diagnosis” to quote the 2021 Global Initiative for Asthma guidelines. Cough challenge is therefore reserved for the experimental study of the pathophysiology of the cough reflex.

Patient-reported outcomes from the simple “score your cough out of 10” used in the clinic, to validated quality of life instruments such as the Leicester Cough Questionnaire quantify the patient experience which, because of its subjective nature, captures a different facet of the condition of chronic cough [1, 2].

Finally, because cough is forced expulsive manoeuvre, usually against a closed glottis, it is associated with a characteristic sound [3]. Since the 1960s, it has been objectively recorded (see figure 1 [4]) and the fundamental elements of this assessment are essentially unchanged. A microphone captures the sound which is recorded and timed (now digitally). The difficult part, which remains unsolved, is how to convert these recordings into cough counts for continuous real-time analysis. Validated tools, such as the Leicester Cough Monitor (LCM) and VitaloJAK [5, 6], are now accepted, with 24-h recordings used as the primary end-point in trials of anti-tussive therapy [7, 8]. However, the feasibility and utility of such measures in real-world clinical practice remains to be tested.

FIGURE 1
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 1

The essential equipment for cough recording. Microphone in position above the head of bed (left-hand image) and tape recorder system (right image). A: main tape recorder; B: electronic on/off unit; C: playback unit with pre-recorded voice; D: chiming clock with microphone. Reproduced from [4] with permission.

In this issue of ERJ Open Research, Vertigan et al. [9] describe their experiences with using LCM in 174 patients and 15 controls at tertiary outpatient clinics and assess the feasibility and clinical utility of objective cough frequency monitoring. The analyses were retrospective, but reveal interesting insights into the practical application of such technology. So, should non-specialists invest in a cough recorder for their clinics?

In terms of feasibility, the majority of both patients and clinicians were positive about using the cough monitors. Approximately three quarters of patients were positive about wearing the monitoring device and could use it correctly and 93% of the recordings were interpretable. The time required for setting up equipment and patient explanation (such as checking batteries, printing instructions, testing, and explaining the instructions to the patients) was between 10 and 20 min in total. Since the LCM uses a computer-based algorithm to “listen” for cough and cough-like sounds, the analysis time per recording averaged a mere 10 min, so in terms of practicality of use of the LCM seems feasible.

However, there is a major limitation inherent in existing cough recording technologies. All current systems record ambient sound for subsequent analysis. We have previously noted a marked reluctance in both patients and relatives to the personal intrusion of unfiltered sound recordings [10]. This is confirmed by the present study in that a quarter of the patients would not agree to carry the device. In an ongoing cough treatment study, 30 chronic cough patients wore the LCM on several occasions without major complaint, but all had meticulous information and instruction about the purpose, use and personal integrity of the recordings (unpublished data; Eva Millqvist). Until such issues of privacy and confidentiality are solved, such as by real-time analysis within the device and the subsequent logging of cough sounds alone, then widespread adoption outside of clinical trials is unlikely.

The authors claim that 24-h cough monitoring was valuable for speech pathologists in planning individual treatments based on a temporal pattern of cough frequency. However, such evaluation requires considerable experience. In their figure 2, they present a “typical” hourly breakdown of cough recording. It shows more or less continual, but intermittent coughing over the whole day. This is a most unusual finding since cough typically diminishes when the patient is asleep to ∼10% of the awake cough frequency. Indeed, this observation is confirmed by their own data comparing daytime and night-time cough (see table 4 in Vertigan et al. [9]).

Furthermore, they claim that cough frequency data is useful for clinicians in evaluating therapeutic responses. However, these were uncontrolled observations and the experience in recent large randomised controlled trials using 24-h cough monitoring is that placebo responses are observed in up to 50% of patients [11], a similar figure to that observed by Vertigan et al. [9].

Perhaps the most interesting observation was the inclusion of 50 patients with inducible laryngeal obstruction and 21 with a diagnosis of severe asthma. These patient groups exhibited cough counts which were very similar to their patients characterised as refractory chronic cough. The authors come to the surprising conclusion that “cough is increased not only in chronic refractory cough but in other diseases”. If one looks at the demographics of these other patients, they are predominantly middle-aged women in their sixth decade and three quarters are female (table 1 in Vertigan et al. [9]). This is exactly the characteristics described in over 10 000 patients presenting to specialist cough clinics worldwide [12]. Given this remarkable similarity is it not more likely that these “other diseases” in fact represent different presentations of the underlying diagnosis of refractory chronic cough?

In support of this hypothesis, patients were administered the Laryngeal Hypersensitivity Questionnaire (LHQ) with the majority scoring outside the established normal range. The LHQ shares several questions with the Hull Airways Reflux Questionnaire (HARQ) which was administered to nearly 2000 patients with refractory or unexplained chronic cough, 95% of whom scored above the upper limit of normal [13]. The HARQ was designed around the known pathophysiology of extra-oesophageal or airway reflux, suggesting a common aetiology may underlie coughing in these diagnoses.

In summary, Vertigan et al. [9] analysed the feasibility of LCM and identified several possibilities and obstacles to its use in real-world practice. Advances in cough assessments and technology will, in future, overcome these difficulties and continuous real time cough monitoring will then provide a valuable tool in diagnosis and management, whatever label is placed on our patients who suffer greatly from the disease of chronic cough.

Footnotes

  • Provenance: Commissioned article, peer reviewed.

  • Conflict of interest: J-H. Lee has no conflict of interest to declare.

  • Conflict of interest: W-J. Song reports grants from MSD and AstraZeneca; consulting fees from MSD and AstraZeneca; and lecture fees from MSD, AstraZeneca, GlaxoSmithKline (GSK) and Novartis.

  • Conflict of interest: E. Millqvist has no conflict of interest to declare.

  • Conflict of interest: A.H. Morice has received consulting fees from Bayer, Bellus, Boehringer Ingelheim, Merck, Pfizer, Proctor & Gamble and Shionogi; lecture fees from Boehringer Ingelheim and AstraZeneca; and grant support from Proctor & Gamble, Merck, Afferent and Infirst.

  • Received August 25, 2021.
  • Accepted September 13, 2021.
  • Copyright ©The authors 2021
http://creativecommons.org/licenses/by-nc/4.0/

This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact permissions{at}ersnet.org

References

  1. ↵
    1. Birring SS,
    2. Prudon B,
    3. Carr AJ, et al.
    Development of a symptom specific health status measure for patients with chronic cough: Leicester Cough Questionnaire (LCQ). Thorax 2003; 58: 339–343. doi:10.1136/thorax.58.4.339
    OpenUrlAbstract/FREE Full Text
  2. ↵
    1. Morice AH,
    2. Millqvist E,
    3. Bieksiene K, et al.
    ERS guidelines on the diagnosis and treatment of chronic cough in adults and children. Eur Respir J 2020; 55: 1901136. doi:10.1183/13993003.01136-2019
    OpenUrlAbstract/FREE Full Text
  3. ↵
    1. Morice A,
    2. Fontana G,
    3. Belvisi M, et al.
    ERS guidelines on the assessment of cough. Eur Respir J 2007; 29: 1256–1276. doi:10.1183/09031936.00101006
    OpenUrlFREE Full Text
  4. ↵
    1. Woolf C,
    2. Rosenberg A
    . Objective assessment of cough suppressants under clinical conditions using a tape recorder system. Thorax 1964; 19: 125–130. doi:10.1136/thx.19.2.125
    OpenUrlFREE Full Text
  5. ↵
    1. Birring SS,
    2. Fleming T,
    3. Matos S, et al.
    The Leicester Cough Monitor: preliminary validation of an automated cough detection system in chronic cough. Eur Respir J 2008; 31: 1013–1018. doi:10.1183/09031936.00057407
    OpenUrlAbstract/FREE Full Text
  6. ↵
    1. Smith JA,
    2. Holt K,
    3. Dockry R, et al.
    Performance of a digital signal processing algorithm for the accurate quantification of cough frequency. Eur Respir J 2021; 58: 2004271. doi:10.1183/13993003.04271-2020
    OpenUrlAbstract/FREE Full Text
  7. ↵
    1. Muccino DR,
    2. Morice AH,
    3. Birring SS, et al.
    Design and rationale of two phase 3 randomised controlled trials (COUGH-1 and COUGH-2) of gefapixant, a P2X3 receptor antagonist, in refractory or unexplained chronic cough. ERJ Open Res 2020; 6: 00284-2020. doi:10.1183/23120541.00284-2020
    OpenUrlAbstract/FREE Full Text
  8. ↵
    1. Ludbrook VJ,
    2. Hanrott KE,
    3. Kreindler JL, et al.
    Adaptive study design to assess effect of TRPV4 inhibition in patients with chronic cough. ERJ Open Res 2021; 7: 00269-2021. doi:10.1183/23120541.00269-2021
  9. ↵
    1. Vertigan AE,
    2. Kapela SL,
    3. Birring SS, et al.
    Feasibility and clinical utility of ambulatory cough monitoring in an outpatient clinical setting: a real-world retrospective evaluation. ERJ Open Res 2021; 7: 00319-2021. doi:10.1183/23120541.00319-2021
    OpenUrlAbstract/FREE Full Text
  10. ↵
    1. Crooks MG,
    2. den Brinker A,
    3. Hayman Y, et al.
    Continuous cough monitoring using ambient sound recording during convalescence from a COPD exacerbation. Lung 2017; 195: 289–294. doi:10.1007/s00408-017-9996-2
    OpenUrl
  11. ↵
    1. McGarvey L,
    2. Birring S,
    3. Morice A, et al.
    Late breaking abstract - two phase 3 randomized clinical trials of Gefapixant, a P2X3 receptor antagonist, in refractory or unexplained chronic cough (COUGH-1 and COUGH-2). Eur Respir J 2020; 56: Suppl. 64, 3800.
    OpenUrlCrossRef
  12. ↵
    1. Morice AH,
    2. Jakes AD,
    3. Faruqi S, et al.
    A worldwide survey of chronic cough: a manifestation of enhanced somatosensory response. Eur Respir J 2014; 44: 1149–1155. doi:10.1183/09031936.00217813
    OpenUrlAbstract/FREE Full Text
  13. ↵
    1. Morice AH
    . On chronic cough diagnosis, classification, and treatment. Lung 2021; 199: 433–434. doi:10.1007/s00408-021-00452-8
    OpenUrl
PreviousNext
Back to top
Vol 7 Issue 4 Table of Contents
ERJ Open Research: 7 (4)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Objective cough frequency monitoring in real-world practice
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
Objective cough frequency monitoring in real-world practice
Ji-Hyang Lee, Woo-Jung Song, Eva Millqvist, Alyn H. Morice
ERJ Open Research Oct 2021, 7 (4) 00545-2021; DOI: 10.1183/23120541.00545-2021

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Objective cough frequency monitoring in real-world practice
Ji-Hyang Lee, Woo-Jung Song, Eva Millqvist, Alyn H. Morice
ERJ Open Research Oct 2021, 7 (4) 00545-2021; DOI: 10.1183/23120541.00545-2021
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • A mechanistic insight into severe COPD
  • Weed, sex and influenza
  • Lung transplantation outcome in adult surfactant-related ILD
Show more Editorials

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About ERJ Open Research

  • Editorial board
  • Journal information
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Online ISSN: 2312-0541

Copyright © 2023 by the European Respiratory Society